Bio-Techne CorporationFind Ratings Reports
BIO-TECHNE CORP's gross profit margin for the second quarter of its fiscal year 2021 is essentially unchanged when compared to the same period a year ago. Even though sales increased, the net income has decreased. BIO-TECHNE CORP is extremely liquid. Currently, the Quick Ratio is 3.50 which clearly shows the ability to cover any short-term cash needs. TECH managed to increase the liquidity from the same period a year ago, despite already having very strong liquidity to begin with. This would indicate improved cash flow.
During the same period, stockholders' equity ("net worth") has increased by 15.00% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q2 FY21||Q2 FY20|
|Net Sales ($mil)||224.25||184.93|
|Net Income ($mil)||46.27||119.62|
|Balance Sheet||Q2 FY21||Q2 FY20|
|Cash & Equiv. ($mil)||282.95||243.95|
|Total Assets ($mil)||2067.87||1998.42|
|Total Debt ($mil)||305.12||464.04|
|Profitability||Q2 FY21||Q2 FY20|
|Gross Profit Margin||76.6||76.76|
|Return on Assets||8.46||9.76|
|Return on Equity||11.5||14.75|
|Debt||Q2 FY21||Q2 FY20|
|Share Data||Q2 FY21||Q2 FY20|
|Shares outstanding (mil)||38.77||38.28|
|Div / share||0.32||0.32|
|Book value / share||39.26||34.57|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||201753.0||160461.0|
BUY. BIO-TECHNE CORP's P/E ratio indicates a significant premium compared to an average of 53.90 for the Chemical Manufacturing subsector and a significant premium compared to the S&P 500 average of 43.53. To use another comparison, its price-to-book ratio of 10.32 indicates a significant premium versus the S&P 500 average of 4.31 and a significant discount versus the subsector average of 14.36. The price-to-sales ratio is well above both the S&P 500 average and the subsector average, indicating a premium. The valuation analysis reveals that, BIO-TECHNE CORP seems to be trading at a premium to investment alternatives.
|TECH 92.50||Peers 80.41||TECH 62.87||Peers 76.40|
Premium. A higher P/E ratio than its peers can signify a more expensive stock or higher growth expectations.
TECH is trading at a premium to its peers.
Discount. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
TECH is trading at a discount to its peers.
|TECH 58.55||Peers 37.66||TECH 24.47||Peers 2.08|
Premium. A higher price-to-projected earnings ratio than its peers can signify a more expensive stock or higher future growth expectations.
TECH is trading at a significant premium to its peers.
Premium. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
TECH trades at a significant premium to its peers.
|TECH 10.32||Peers 14.36||TECH -11.70||Peers 3.56|
Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
TECH is trading at a significant discount to its peers.
Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
However, TECH is expected to significantly trail its peers on the basis of its earnings growth rate.
|TECH 19.66||Peers 12.17||TECH 7.28||Peers 16.27|
Premium. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
TECH is trading at a significant premium to its subsector.
Lower. A sales growth rate that trails the subsector implies that a company is losing market share.
TECH significantly trails its peers on the basis of sales growth.